These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 12452731)

  • 1. Labelling and 'Dear Doctor' letters: are they noncommittal?
    van Grootheest AC; Edwards IR
    Drug Saf; 2002; 25(15):1051-5. PubMed ID: 12452731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contraindication labelling changes in the United States and Germany.
    Garbe E; Andersohn F
    Eur J Clin Pharmacol; 2007 Jan; 63(1):87-93. PubMed ID: 17124576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters.
    Weatherby LB; Walker AM; Fife D; Vervaet P; Klausner MA
    Pharmacoepidemiol Drug Saf; 2001 May; 10(3):211-8. PubMed ID: 11501334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of wording in "Dear doctor" letters and in black box labels.
    Weatherby LB; Nordstrom BL; Fife D; Walker AM
    Clin Pharmacol Ther; 2002 Dec; 72(6):735-42. PubMed ID: 12496755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical counseling: Between evidence-based medicine and profits.
    Egorova SN; Akhmetova T
    Int J Risk Saf Med; 2015; 27 Suppl 1():S87-8. PubMed ID: 26639727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of safety-related regulatory action on clinical practice: a systematic review.
    Piening S; Haaijer-Ruskamp FM; de Vries JT; van der Elst ME; de Graeff PA; Straus SM; Mol PG
    Drug Saf; 2012 May; 35(5):373-85. PubMed ID: 22480319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Autonomy attitudes in the treatment compliance of a cohort of subjects with continuous psychotropic drug administration].
    Baumann M; Trincard M
    Encephale; 2002; 28(5 Pt 1):389-96. PubMed ID: 12386539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patients.
    Schächtele S; Tümena T; Gaßmann KG; Fromm MF; Maas R
    Dtsch Arztebl Int; 2014 Apr; 111(15):255-63. PubMed ID: 24776610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice?
    Le Jeunne C; Billon N; Dandon A; ; Berdaï D; Adgibi Y; Bergmann JF; Bordet R; Carpentier A; Cohn E; Courcier S; Girault D; Goni S; Jolliet P; Liard F; Prot-Labarthe S; Simon T; Vernotte C; Westerloppe J
    Therapie; 2013; 68(4):225-39. PubMed ID: 23981260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infovigilance: reporting errors in official drug information sources.
    Fusier I; Tollier C; Husson MC
    Pharm World Sci; 2005 Jun; 27(3):166-9. PubMed ID: 16096882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Communicating safety information to physicians: an examination of dear doctor letters.
    Mazor KM; Andrade SE; Auger J; Fish L; Gurwitz JH
    Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):869-75. PubMed ID: 15818636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.
    Uhl K; Kennedy DL; Kweder SL
    Drug Saf; 2002; 25(12):885-92. PubMed ID: 12241129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of a "Dear Doctor letter" to alert healthcare providers to new recommendations for vitamin D administration.
    Théophile H; Miremont-Salamé G; Robinson P; Moore N; Bégaud B; Haramburu F
    Eur J Clin Pharmacol; 2011 Jul; 67(7):681-6. PubMed ID: 21597972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological Basis for Therapeutics. Pharmacological Analysis of Summary of Product Characteristics (SPC) for Physicians].
    Lechat P
    Therapie; 2015; 70(5):403-14. PubMed ID: 26109291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Physician versus 'off-label" ordinance].
    Kordus K; Spiewak R
    Przegl Lek; 2015; 72(1):38-41. PubMed ID: 26076577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attitudes and experiences of community pharmacists towards paediatric off-label prescribing: a prospective survey.
    Stewart D; Rouf A; Snaith A; Elliott K; Helms PJ; McLay JS
    Br J Clin Pharmacol; 2007 Jul; 64(1):90-5. PubMed ID: 17324238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacists and patients feedback on empirically designed prescription warning labels: a qualitative study.
    Shiyanbola OO; Smith PD; Huang YM; Mansukhani SG
    Int J Clin Pharm; 2017 Feb; 39(1):187-195. PubMed ID: 28070688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [INFORMATION ON DRUGS].
    Foucher JP
    J Int Bioethique Ethique Sci; 2015 Mar; 26(1):65-72, 101-2. PubMed ID: 26606769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk Communication and the Pharmaceutical Industry: what is the reality?
    Edwards B; Chakraborty S
    Drug Saf; 2012 Nov; 35(11):1027-40. PubMed ID: 23061779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Communication of medical product risk: how effective is effective enough?
    Goldman SA
    Drug Saf; 2004; 27(8):519-34. PubMed ID: 15154825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.